Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

ABSTRACT: Despite mass drug administration programmes with praziquantel, the prevalence of schistosomiasis remains high. A vaccine is urgently needed to control transmission of this debilitating disease. As some promising schistosomiasis vaccine candidates are moving through pre-clinical and clinical testing, we review the immunological challenges that these vaccine candidates may encounter in transitioning through the clinical trial phases in endemic settings. Prior exposure of the target population to schistosomes and other infections may impact vaccine response and efficacy and therefore requires considerable attention. Schistosomes are known for their potential to induce T-reg/IL-10 mediated immune suppression in populations which are chronically infected. Moreover, endemicity of schistosomiasis

SUBMITTER: Driciru E 

PROVIDER: S-EPMC7970007 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature